Antithrombotic treatment in transcatheter aortic valve implantation: Insights for cerebrovascular and bleeding events

Josep Rodés-Cabau, Harold L. Dauerman, Mauricio G Cohen, Roxana Mehran, Eric M. Small, Susan S. Smyth, Marco A. Costa, Jessica L. Mega, Michelle L. O'Donoghue, E. Magnus Ohman, Richard C. Becker

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Transcatheter aortic valve implantation (TAVI) has emerged as a therapeutic alternative for patients with symptomatic aortic stenosis at high or prohibitive surgical risk. However, patients undergoing TAVI are also at high risk for both bleeding and stroke complications, and specific mechanical aspects of the procedure itself can increase the risk of these complications. The mechanisms of periprocedural bleeding complications seem to relate mainly to vascular/access site complications (related to the use of large catheters in a very old and frail elderly population), whereas the pathophysiology of cerebrovascular events remains largely unknown. Further, although mechanical complications, especially the interaction between the valve prosthesis and the native aortic valve, may play a major role in events that occur during TAVI, post-procedural events might also be related to a prothrombotic environment or state generated by the implanted valve, the occurrence of atrial arrhythmias, and associated comorbidities. Antithrombotic therapy in the setting of TAVI has been empirically determined, and unfractionated heparin during the procedure followed by dual antiplatelet therapy with aspirin (indefinitely) and clopidogrel (1 to 6 months) is the most commonly recommended treatment. However, bleeding and cerebrovascular events are common; these may be modifiable with optimization of periprocedural and post-procedural pharmacology. Further, as the field of antiplatelet and anticoagulant therapy evolves, potential drug combinations will multiply, introducing variability in treatment. Randomized trials are the best path forward to determine the balance between the efficacy and risks of antithrombotic treatment in this high risk-population.

Original languageEnglish
Pages (from-to)2349-2359
Number of pages11
JournalJournal of the American College of Cardiology
Volume62
Issue number25
DOIs
StatePublished - Dec 24 2013

Fingerprint

Hemorrhage
clopidogrel
Therapeutics
Frail Elderly
Aortic Valve Stenosis
Drug Combinations
Transcatheter Aortic Valve Replacement
Aortic Valve
Anticoagulants
Population
Aspirin
Prostheses and Implants
Blood Vessels
Heparin
Comorbidity
Cardiac Arrhythmias
Catheters
Stroke
Pharmacology

Keywords

  • antiplatelet agents
  • bleeding
  • platelets
  • stroke
  • transcatheter aortic valve implantation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antithrombotic treatment in transcatheter aortic valve implantation : Insights for cerebrovascular and bleeding events. / Rodés-Cabau, Josep; Dauerman, Harold L.; Cohen, Mauricio G; Mehran, Roxana; Small, Eric M.; Smyth, Susan S.; Costa, Marco A.; Mega, Jessica L.; O'Donoghue, Michelle L.; Ohman, E. Magnus; Becker, Richard C.

In: Journal of the American College of Cardiology, Vol. 62, No. 25, 24.12.2013, p. 2349-2359.

Research output: Contribution to journalArticle

Rodés-Cabau, J, Dauerman, HL, Cohen, MG, Mehran, R, Small, EM, Smyth, SS, Costa, MA, Mega, JL, O'Donoghue, ML, Ohman, EM & Becker, RC 2013, 'Antithrombotic treatment in transcatheter aortic valve implantation: Insights for cerebrovascular and bleeding events', Journal of the American College of Cardiology, vol. 62, no. 25, pp. 2349-2359. https://doi.org/10.1016/j.jacc.2013.03.029
Rodés-Cabau, Josep ; Dauerman, Harold L. ; Cohen, Mauricio G ; Mehran, Roxana ; Small, Eric M. ; Smyth, Susan S. ; Costa, Marco A. ; Mega, Jessica L. ; O'Donoghue, Michelle L. ; Ohman, E. Magnus ; Becker, Richard C. / Antithrombotic treatment in transcatheter aortic valve implantation : Insights for cerebrovascular and bleeding events. In: Journal of the American College of Cardiology. 2013 ; Vol. 62, No. 25. pp. 2349-2359.
@article{c17834efc6884053b0ac335dc11de546,
title = "Antithrombotic treatment in transcatheter aortic valve implantation: Insights for cerebrovascular and bleeding events",
abstract = "Transcatheter aortic valve implantation (TAVI) has emerged as a therapeutic alternative for patients with symptomatic aortic stenosis at high or prohibitive surgical risk. However, patients undergoing TAVI are also at high risk for both bleeding and stroke complications, and specific mechanical aspects of the procedure itself can increase the risk of these complications. The mechanisms of periprocedural bleeding complications seem to relate mainly to vascular/access site complications (related to the use of large catheters in a very old and frail elderly population), whereas the pathophysiology of cerebrovascular events remains largely unknown. Further, although mechanical complications, especially the interaction between the valve prosthesis and the native aortic valve, may play a major role in events that occur during TAVI, post-procedural events might also be related to a prothrombotic environment or state generated by the implanted valve, the occurrence of atrial arrhythmias, and associated comorbidities. Antithrombotic therapy in the setting of TAVI has been empirically determined, and unfractionated heparin during the procedure followed by dual antiplatelet therapy with aspirin (indefinitely) and clopidogrel (1 to 6 months) is the most commonly recommended treatment. However, bleeding and cerebrovascular events are common; these may be modifiable with optimization of periprocedural and post-procedural pharmacology. Further, as the field of antiplatelet and anticoagulant therapy evolves, potential drug combinations will multiply, introducing variability in treatment. Randomized trials are the best path forward to determine the balance between the efficacy and risks of antithrombotic treatment in this high risk-population.",
keywords = "antiplatelet agents, bleeding, platelets, stroke, transcatheter aortic valve implantation",
author = "Josep Rod{\'e}s-Cabau and Dauerman, {Harold L.} and Cohen, {Mauricio G} and Roxana Mehran and Small, {Eric M.} and Smyth, {Susan S.} and Costa, {Marco A.} and Mega, {Jessica L.} and O'Donoghue, {Michelle L.} and Ohman, {E. Magnus} and Becker, {Richard C.}",
year = "2013",
month = "12",
day = "24",
doi = "10.1016/j.jacc.2013.03.029",
language = "English",
volume = "62",
pages = "2349--2359",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "25",

}

TY - JOUR

T1 - Antithrombotic treatment in transcatheter aortic valve implantation

T2 - Insights for cerebrovascular and bleeding events

AU - Rodés-Cabau, Josep

AU - Dauerman, Harold L.

AU - Cohen, Mauricio G

AU - Mehran, Roxana

AU - Small, Eric M.

AU - Smyth, Susan S.

AU - Costa, Marco A.

AU - Mega, Jessica L.

AU - O'Donoghue, Michelle L.

AU - Ohman, E. Magnus

AU - Becker, Richard C.

PY - 2013/12/24

Y1 - 2013/12/24

N2 - Transcatheter aortic valve implantation (TAVI) has emerged as a therapeutic alternative for patients with symptomatic aortic stenosis at high or prohibitive surgical risk. However, patients undergoing TAVI are also at high risk for both bleeding and stroke complications, and specific mechanical aspects of the procedure itself can increase the risk of these complications. The mechanisms of periprocedural bleeding complications seem to relate mainly to vascular/access site complications (related to the use of large catheters in a very old and frail elderly population), whereas the pathophysiology of cerebrovascular events remains largely unknown. Further, although mechanical complications, especially the interaction between the valve prosthesis and the native aortic valve, may play a major role in events that occur during TAVI, post-procedural events might also be related to a prothrombotic environment or state generated by the implanted valve, the occurrence of atrial arrhythmias, and associated comorbidities. Antithrombotic therapy in the setting of TAVI has been empirically determined, and unfractionated heparin during the procedure followed by dual antiplatelet therapy with aspirin (indefinitely) and clopidogrel (1 to 6 months) is the most commonly recommended treatment. However, bleeding and cerebrovascular events are common; these may be modifiable with optimization of periprocedural and post-procedural pharmacology. Further, as the field of antiplatelet and anticoagulant therapy evolves, potential drug combinations will multiply, introducing variability in treatment. Randomized trials are the best path forward to determine the balance between the efficacy and risks of antithrombotic treatment in this high risk-population.

AB - Transcatheter aortic valve implantation (TAVI) has emerged as a therapeutic alternative for patients with symptomatic aortic stenosis at high or prohibitive surgical risk. However, patients undergoing TAVI are also at high risk for both bleeding and stroke complications, and specific mechanical aspects of the procedure itself can increase the risk of these complications. The mechanisms of periprocedural bleeding complications seem to relate mainly to vascular/access site complications (related to the use of large catheters in a very old and frail elderly population), whereas the pathophysiology of cerebrovascular events remains largely unknown. Further, although mechanical complications, especially the interaction between the valve prosthesis and the native aortic valve, may play a major role in events that occur during TAVI, post-procedural events might also be related to a prothrombotic environment or state generated by the implanted valve, the occurrence of atrial arrhythmias, and associated comorbidities. Antithrombotic therapy in the setting of TAVI has been empirically determined, and unfractionated heparin during the procedure followed by dual antiplatelet therapy with aspirin (indefinitely) and clopidogrel (1 to 6 months) is the most commonly recommended treatment. However, bleeding and cerebrovascular events are common; these may be modifiable with optimization of periprocedural and post-procedural pharmacology. Further, as the field of antiplatelet and anticoagulant therapy evolves, potential drug combinations will multiply, introducing variability in treatment. Randomized trials are the best path forward to determine the balance between the efficacy and risks of antithrombotic treatment in this high risk-population.

KW - antiplatelet agents

KW - bleeding

KW - platelets

KW - stroke

KW - transcatheter aortic valve implantation

UR - http://www.scopus.com/inward/record.url?scp=84881530408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881530408&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.03.029

DO - 10.1016/j.jacc.2013.03.029

M3 - Article

AN - SCOPUS:84881530408

VL - 62

SP - 2349

EP - 2359

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 25

ER -